{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:41:08Z","timestamp":1773060068980,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Infantile hemangioma (IH) is the most common benign tumor of infancy. For children with IH who require treatment, propranolol and other beta blockers have been shown to be safe and effective. Although consensus guidelines for managing IH have been published, anecdotal experience suggests that there remain variations in management. This study was performed to document these variations amongst providers and to identify areas for future research. We conducted an Internet-based survey of clinicians who treat patients with IH. Hypothetical cases and management scenarios were presented. Twenty-nine respondents participated in the survey. Most respondents use generic propranolol in infants with growing IH of the head and neck, with a goal dose of 2\u00a0mg\/kg\/d, until ~1 year of age. A variety of management strategies were documented including which patients should be treated, optimal dose and duration of therapy, how patients should be monitored, which patients should get additional workup, how propranolol should best be discontinued, and how often to see patients in follow-up. This study demonstrates wide practice variations in managing patients with IH. Further research is indicated to address these variations and develop additional\/updated evidence-based guidelines.<\/jats:p>","DOI":"10.1097\/mph.0000000000002759","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:27Z","timestamp":1695686427000},"page":"452-460","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Practice Variations in Managing Infantile Hemangiomas"],"prefix":"10.1097","volume":"45","author":[{"given":"Thomas W.","family":"McLean","sequence":"first","affiliation":[{"name":"Vascular Anomalies Special Interest Group of the American Society of Pediatric Hematology\/Oncology and the Divisions of Pediatric Hematology\/Oncology, Wake Forest University School of Medicine, Winston-Salem"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra J.","family":"Borst","sequence":"additional","affiliation":[{"name":"The Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne M.","family":"Hammill","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ionela","family":"Iacobas","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor University, Texas Children\u2019s Hospital, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Autumn","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Texas Health Science Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tishi","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith F.","family":"Margolin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor University, Texas Children\u2019s Hospital, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry L.","family":"Bayliff","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Kentucky, Lexington, KY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Blatt","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of North Carolina, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0140-6736(16)00645-0","article-title":"Infantile haemangioma","volume":"390","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","journal-title":"Lancet"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MPH.0000000000002384","article-title":"Infantile hemangioma: a current review","volume":"44","author":"Pahl","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"Leaute-Labreze","year":"2008","journal-title":"N Engl J Med"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00431-015-2561-1","article-title":"Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma","volume":"174","author":"Aly","year":"2015","journal-title":"Eur J Pediatr"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"e1060","DOI":"10.1542\/peds.2015-2485","article-title":"Diagnosis and management of infantile hemangioma","volume":"136","author":"Darrow","year":"2015","journal-title":"Pediatrics"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00431-015-2570-0","article-title":"Treatment of infantile haemangiomas: recommendations of a European expert group","volume":"174","author":"Hoeger","year":"2015","journal-title":"Eur J Pediatr"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1542\/peds.2010-0029","article-title":"A randomized controlled trial of propranolol for infantile hemangiomas","volume":"128","author":"Hogeling","year":"2011","journal-title":"Pediatrics"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"e20160353","DOI":"10.1542\/peds.2016-0353","article-title":"Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review","volume":"138","author":"Leaute-Labreze","year":"2016","journal-title":"Pediatrics"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1056\/NEJMc1503811","article-title":"Oral propranolol for infantile hemangioma","volume":"373","author":"Leaute-Labreze","year":"2015","journal-title":"N Engl J Med"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.joms.2016.03.004","article-title":"Oral propranolol for the treatment of infantile hemangiomas in the post-proliferative phase: a-single center retrospective study of 31 cases","volume":"74","author":"Tian","year":"2016","journal-title":"J Oral Maxillofac Surg"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"e20173866","DOI":"10.1542\/peds.2017-3866","article-title":"Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma","volume":"142","author":"Baselga","year":"2018","journal-title":"Pediatrics"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1542\/peds.2017-3783","article-title":"Safety of oral propranolol for infantile hemangioma","volume":"141","author":"Droitcourt","year":"2018","journal-title":"Pediatrics"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1542\/peds.2012-1691","article-title":"Initiation and use of propranolol for infantile hemangioma: report of a consensus conference","volume":"131","author":"Drolet","year":"2013","journal-title":"Pediatrics"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"e20183475","DOI":"10.1542\/peds.2018-3475","article-title":"Clinical practice guideline for the management of infantile hemangiomas","volume":"143","author":"Krowchuk","year":"2019","journal-title":"Pediatrics"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"e20191628","DOI":"10.1542\/peds.2019-1628","article-title":"The infantile hemangioma referral score: a validated tool for physicians","volume":"145","author":"Leaute-Labreze","year":"2020","journal-title":"Pediatrics"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/pde.12022","article-title":"Propranolol treatme","volume":"30","author":"Martin","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/00034894221089758","article-title":"Should propranolol remain the gold standard for treatment of infantile hemangioma? A systematic review and meta-analysis of propranolol versus atenolol","volume":"132","author":"Chen","year":"2023","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4103\/jiaps.jiaps_3_21","article-title":"Oral atenolol versus propranolol in the treatment of infantile hemangioma: a systematic review and meta-analysis","volume":"27","author":"Pattanshetti","year":"2022","journal-title":"J Indian Assoc Pediatr Surg"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamapediatrics.2021.4565","article-title":"Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial","volume":"176","author":"Pope","year":"2022","journal-title":"JAMA Pediatr"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1525-1470.2012.01723.x","article-title":"Topical timolol for small hemangiomas of infancy","volume":"30","author":"Moehrle","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/pde.14281","article-title":"Retrospective case series of increased oral propranolol dosage for infantile hemangiomas","volume":"37","author":"Huang","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s12519-019-00285-9","article-title":"Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies","volume":"15","author":"Yang","year":"2019","journal-title":"World J Pediatr"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.abd.2022.04.008","article-title":"Early propranolol treatment of infantile hemangiomas improves outcome","volume":"98","author":"Giachetti","year":"2023","journal-title":"An Bras Dermatol"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/pde.15198","article-title":"Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate","volume":"40","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/pde.14966","article-title":"Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age","volume":"39","author":"Gatts","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"e20151754","DOI":"10.1542\/peds.2015-1754","article-title":"Rebound growth of infantile hemangiomas after propranolol therapy","volume":"137","author":"Shah","year":"2016","journal-title":"Pediatrics"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamapediatrics.2016.0824","article-title":"Reevaluating the need for electrocardiograms prior to initiation of treatment with propranolol for infantile hemangiomas","volume":"170","author":"Streicher","year":"2016","journal-title":"JAMA Pediatr"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1525-1470.2011.01420.x","article-title":"Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas","volume":"28","author":"Horii","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.19472","article-title":"Routine liver ultrasound screening does not alter clinical management in a cohort study of multiple cutaneous infantile haemangioma","volume":"184","author":"Mahon","year":"2021","journal-title":"Br J Dermatol"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/SAP.0000000000000506","article-title":"is propranolol safe and effective for outpatient use for infantile hemangioma? A prospective study of 679 cases from one center in China","volume":"76","author":"Chang","year":"2016","journal-title":"Ann Plast Surg"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/pde.14196","article-title":"Management of infantile hemangiomas during the COVID pandemic","volume":"37","author":"Frieden","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"R33-20250804","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/ajd.12600","article-title":"Consensus statement for the treatment of infantile haemangiomas with propranolol","volume":"58","author":"Smithson","year":"2017","journal-title":"Australas J Dermatol"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bjd.16779","article-title":"Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines","volume":"179","author":"Solman","year":"2018","journal-title":"Br J Dermatol"},{"key":"R35-20250804","doi-asserted-by":"crossref","first-page":"43292","DOI":"10.1038\/srep43292","article-title":"When to stop propranolol for infantile hemangioma","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"R36-20250804","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamadermatol.2021.0469","article-title":"Clinical features, prognostic factors, and treatment interventions for ulceration in patients with infantile hemangioma","volume":"157","author":"Fern\u00e1ndez Faith","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:04:22Z","timestamp":1754337862000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002759","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"2023-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}